Show simple item record

dc.contributor.authorSchullian, P
dc.contributor.authorLaimer, G
dc.contributor.authorJohnston, E
dc.contributor.authorPutzer, D
dc.contributor.authorEberle, G
dc.contributor.authorWidmann, G
dc.contributor.authorScharll, Y
dc.contributor.authorBale, R
dc.coverage.spatialSwitzerland
dc.date.accessioned2023-06-13T12:07:34Z
dc.date.available2023-06-13T12:07:34Z
dc.date.issued2023-01-22
dc.identifierbiology12020175
dc.identifier.citationBiology, 2023, 12 (2), pp. 175 -
dc.identifier.issn2079-7737
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/5843
dc.identifier.eissn2079-7737
dc.identifier.eissn2079-7737
dc.identifier.doi10.3390/biology12020175
dc.description.abstractPURPOSE: To compare the results of a novice with those of experienced interventional radiologists (IRs) for stereotactic radiofrequency ablation (SRFA) of malignant liver tumors in terms of safety, technical success, and local tumor control. METHODS: A database, including all SRFA procedures performed in a single center between January 2011 and December 2018 was retrospectively analyzed. A total of 39 ablation sessions performed by a novice IR were compared to the results of three more experienced IRs. Comparative SRFA sessions were selected using propensity score matching considering tumor type, age, sex, tumor size, and tumor number as matching variables. Overall, 549 target tumors were treated in 273 sessions. Median tumor size was 2.2 cm (1.0-8.5 cm) for 178 hepatocellular carcinomas (HCCs) and 3.0 cm (0.5-13.0 cm) for 371 metastases. A median of 2 (1-11) tumors were treated per session. RESULTS: No significant differences were observed when comparing the results of more experienced IRs with those of a novice IR regarding the rates of major complications (6.8% [16/234] vs. 5.1% [2/39]; p = 0.477), mortality (1.3% [2/234] vs. 0% [0/39]; p = 0.690), primary technical efficacy (98.5% [525/533] vs. 98.9% [94/95]; p = 0.735), and local recurrence (5.6% [30/533] vs. 5.3% [5/95]; p = 0.886). However, the median planning/placement time was significantly shorter for the experienced IRs (92 min vs. 119 min; p = 0.002). CONCLUSIONS: SRFA is a safe, effective, and reliable treatment option for malignant liver tumors and favorable outcomes can be achieved even by inexperienced operators with minimal supervision.
dc.formatElectronic
dc.format.extent175 -
dc.languageeng
dc.language.isoeng
dc.publisherMDPI
dc.relation.ispartofBiology
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectliver
dc.subjectradiofrequency ablation
dc.subjectreliability
dc.subjectstereotaxy
dc.subjecttumor
dc.titleReliability of Stereotactic Radiofrequency Ablation (SRFA) for Malignant Liver Tumors: Novice versus Experienced Operators.
dc.typeJournal Article
dcterms.dateAccepted2023-01-20
dc.date.updated2023-06-08T10:49:21Z
rioxxterms.versionVoR
rioxxterms.versionofrecord10.3390/biology12020175
rioxxterms.licenseref.startdate2023-01-22
rioxxterms.typeJournal Article/Review
pubs.author-urlhttps://www.ncbi.nlm.nih.gov/pubmed/36829454
pubs.issue2
pubs.organisational-group/ICR
pubs.publication-statusPublished online
pubs.publisher-urlhttp://dx.doi.org/10.3390/biology12020175
pubs.volume12
dc.contributor.icrauthorJohnston
icr.provenanceDeposited by Dr Johnston on 2023-06-08. Deposit type is initial. No. of files: 1. Files: Reliability of Stereotactic Radiofrequency Ablation (SRFA) for Malignant Liver Tumors Novice versus Experienced Operators.pdf


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record

http://creativecommons.org/licenses/by/4.0/
Except where otherwise noted, this item's license is described as http://creativecommons.org/licenses/by/4.0/